CO5261605A1 - Compustos farmaceuticos - Google Patents
Compustos farmaceuticosInfo
- Publication number
- CO5261605A1 CO5261605A1 CO00082018A CO00082018A CO5261605A1 CO 5261605 A1 CO5261605 A1 CO 5261605A1 CO 00082018 A CO00082018 A CO 00082018A CO 00082018 A CO00082018 A CO 00082018A CO 5261605 A1 CO5261605 A1 CO 5261605A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- alkanoyl
- group
- substituted
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16290099P | 1999-11-01 | 1999-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5261605A1 true CO5261605A1 (es) | 2003-03-31 |
Family
ID=22587589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00082018A CO5261605A1 (es) | 1999-11-01 | 2000-10-27 | Compustos farmaceuticos |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1230225A2 (fr) |
AR (1) | AR026275A1 (fr) |
AU (1) | AU1071301A (fr) |
CO (1) | CO5261605A1 (fr) |
PE (1) | PE20010854A1 (fr) |
SV (1) | SV2002000205A (fr) |
WO (1) | WO2001032632A2 (fr) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429207B1 (en) | 1997-11-21 | 2002-08-06 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
EP1408980A4 (fr) | 2001-06-21 | 2004-10-20 | Ariad Pharma Inc | Nouvelles quinazolines et leur utilisation |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
WO2003104230A1 (fr) | 2002-06-07 | 2003-12-18 | 協和醱酵工業株式会社 | Derives bicycliques de pyrimidine |
US7423044B2 (en) | 2002-09-05 | 2008-09-09 | Wyeth | Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia |
AR044743A1 (es) * | 2002-09-26 | 2005-10-05 | Nihon Nohyaku Co Ltd | Herbicida, metodo de emplearlo, derivados de tienopirimidina sustituida,compuestos intermediarios, y procedimientos que se utilizan para producirlos, |
US7196106B2 (en) | 2002-11-05 | 2007-03-27 | Merck & Co., Inc | Cyanothiophene derivatives, compositions containing such compounds and methods of use |
KR100772297B1 (ko) * | 2002-11-22 | 2007-11-02 | 니뽄 다바코 산교 가부시키가이샤 | 융합 비시클릭 질소-함유 헤테로사이클 |
US7759336B2 (en) * | 2002-12-10 | 2010-07-20 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
MXPA05011103A (es) | 2003-04-16 | 2005-12-12 | Hoffmann La Roche | Compuestos de quinazolina. |
CN1774250A (zh) | 2003-04-16 | 2006-05-17 | 霍夫曼-拉罗奇有限公司 | 作为治疗诸如类风湿性关节炎的炎性疾病的p38激酶抑制剂的(6-(苯氧基)-吡啶并[3,4-d]嘧啶-2-基)-胺衍生物 |
JP2007501801A (ja) | 2003-08-07 | 2007-02-01 | 日本たばこ産業株式会社 | ピロロ[1,2−b]ピリダジン誘導体 |
WO2005016925A1 (fr) * | 2003-08-14 | 2005-02-24 | Pfizer Limited | Derives d'azaquinazoline |
TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
JPWO2005085210A1 (ja) * | 2004-03-10 | 2008-01-17 | 小野薬品工業株式会社 | ニトリル化合物およびその化合物を有効成分として含有する医薬組成物 |
US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
US7598259B2 (en) | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
PE20060526A1 (es) * | 2004-06-15 | 2006-07-13 | Schering Corp | Compuestos triciclicos como antagonistas de mglur1 |
AU2005290226A1 (en) | 2004-07-16 | 2006-04-06 | Sunesis Pharmaceuticals, Inc. | Thienopyrimidines useful as Aurora kinase inhibitors |
US7928107B2 (en) | 2004-09-02 | 2011-04-19 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
US8283354B2 (en) | 2004-09-02 | 2012-10-09 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
NZ589252A (en) * | 2004-09-02 | 2012-06-29 | Vertex Pharma | Quinazolines useful as inhibitors of voltage-gated sodium channels |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
US20060128710A1 (en) * | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
CA2606760C (fr) | 2005-05-04 | 2014-12-23 | Renovis, Inc. | Composes de tetrahydronaphthyridine et de tetrahydropyrido[4,3-d]pyrimidine et compositions de ceux-ci utiles dans lediraitement des conditions associees aux troubles et dysfonctions neurologiques et inflammatoires |
US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
CN101277939A (zh) * | 2005-09-09 | 2008-10-01 | 布里斯托尔-迈尔斯斯奎布公司 | 无环ikur抑制剂 |
WO2007070872A1 (fr) | 2005-12-15 | 2007-06-21 | Rigel Pharmaceuticals, Inc. | Inhibiteurs de kinase et leurs utilisations |
HUP0501168A3 (en) * | 2005-12-20 | 2007-10-29 | Richter Gedeon Nyrt | 2-(acyl, oxycarbonyl or aminocarbonyl)-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical composition containing them |
HUP0501170A2 (en) * | 2005-12-20 | 2007-09-28 | Richter Gedeon Nyrt | 2-heteroaryl-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical compositions containing them |
CA2630896A1 (fr) * | 2005-12-20 | 2007-06-28 | Richter Gedeon Nyrt. | Nouveaux composes |
ATE479690T1 (de) * | 2005-12-20 | 2010-09-15 | Richter Gedeon Nyrt | Thienoä2,3-büpyridin derivate |
EP1971611B1 (fr) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Composes anti-viraux |
WO2007076034A2 (fr) | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Composes antiviraux |
CN102702194A (zh) | 2005-12-21 | 2012-10-03 | 雅培制药有限公司 | 抗病毒化合物 |
EP2345652A1 (fr) | 2005-12-21 | 2011-07-20 | Abbott Laboratories | Composées antivirales |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
DE102006012251A1 (de) * | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln |
EP1921070A1 (fr) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation |
JP2010510314A (ja) | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス,エルエルシー | 精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法 |
CA2672737A1 (fr) | 2006-12-20 | 2008-11-06 | Abbott Laboratories | Composes antiviraux |
EP2118075A1 (fr) | 2007-02-06 | 2009-11-18 | Boehringer Ingelheim International GmbH | Hétérocycles bicycliques, agents pharmaceutiques contenant ces composés, leur utilisation et leur procédé de préparation |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
WO2008157500A1 (fr) * | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Modulateurs du récepteur cannabinoïde à base d'aminoquinazoline pour le traitement de maladies |
NZ582934A (en) | 2007-08-02 | 2011-10-28 | Recordati Ireland Ltd | Novel heterocyclic compounds as mglu5 antagonists |
TW200922566A (en) | 2007-09-14 | 2009-06-01 | Ortho Mcneil Janssen Pharm | 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
ES2356032T3 (es) | 2007-09-14 | 2011-04-04 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 4-fenil-3,4,5,6-tetrahidro-2h,1'h-[1,4']bipiridinil-2'-onas 1,3'-disustituidas. |
JP5336516B2 (ja) | 2008-02-07 | 2013-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法 |
ES2444128T3 (es) | 2008-05-13 | 2014-02-24 | Astrazeneca Ab | Nueva SAL-554 |
US8648191B2 (en) | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
MX2011002042A (es) | 2008-09-02 | 2011-06-20 | Ortho Mcneil Janssen Pharm | Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico. |
US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
CA2744343A1 (fr) * | 2008-11-19 | 2010-05-27 | Renovis, Inc. | Composes 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine s'utilisant comme modulateurs de la faah et utilisations desdits composes |
EP2373649B1 (fr) | 2008-11-28 | 2013-01-23 | Janssen Pharmaceuticals, Inc. | Dérivés d'indole et de benzoxazine comme modulateurs des récepteurs métabotropiques au glutamate |
SG172060A1 (en) * | 2008-12-09 | 2011-07-28 | Gilead Sciences Inc | Modulators of toll-like receptors |
EP2393780A1 (fr) | 2009-02-04 | 2011-12-14 | Recordati Ireland Limited | Dérivés hétérocycliques en tant qu'antagonistes de mglu5 |
NZ596053A (en) | 2009-05-12 | 2013-05-31 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MX2011011964A (es) | 2009-05-12 | 2012-02-23 | Janssen Pharmaceuticals Inc | Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos. |
WO2011029633A1 (fr) | 2009-09-14 | 2011-03-17 | Recordati Ireland Limited | Antagonistes hétérocycliques de mglu5 |
WO2011106276A1 (fr) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Antagonistes des canaux task |
US20130058915A1 (en) | 2010-03-02 | 2013-03-07 | Children's Medica Center Corporation | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
US20110294879A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
KR101862626B1 (ko) * | 2010-07-09 | 2018-05-31 | 레코르다티 아일랜드 리미티드 | Mglu5 대항체로서의 신 스피로헤테로사이클릭 화합물 |
US20120016021A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
US8551981B2 (en) | 2010-10-08 | 2013-10-08 | Abbvie Inc. | Furo[3,2-d]pyrimidine compounds |
WO2012054724A1 (fr) | 2010-10-21 | 2012-04-26 | Massachusetts Institute Of Technology | Méthodes de traitement de troubles épileptiques |
EP2649069B1 (fr) | 2010-11-08 | 2015-08-26 | Janssen Pharmaceuticals, Inc. | Dérivés de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2 |
US9012448B2 (en) | 2010-11-08 | 2015-04-21 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
JP6353788B2 (ja) | 2012-01-13 | 2018-07-04 | エイシア バイオサイエンシーズ インコーポレイテッド | 抗がん剤としての複素環式化合物およびその使用 |
TWI499591B (zh) | 2013-01-11 | 2015-09-11 | Lilly Co Eli | 雙環嘧啶化合物 |
TW201520219A (zh) | 2013-03-12 | 2015-06-01 | Lilly Co Eli | 咪唑並吡啶化合物 |
TW201500356A (zh) * | 2013-04-12 | 2015-01-01 | Lilly Co Eli | 二氫吡啶并嘧啶化合物 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
EP3019496B1 (fr) | 2013-07-11 | 2019-09-11 | ACEA Therapeutics, Inc. | Dérivés de la pyrimidine comme inhibiteurs des kinases. |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
KR102414246B1 (ko) | 2014-01-21 | 2022-06-27 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
LT3431106T (lt) | 2014-01-21 | 2021-02-10 | Janssen Pharmaceutica Nv | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
US9868744B2 (en) | 2014-04-25 | 2018-01-16 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
CN108290855A (zh) | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途 |
EP3325490B1 (fr) | 2015-07-23 | 2019-12-18 | Takeda Pharmaceutical Company Limited | DÉRIVÉS DE 1,2,3,4-TÉTRAHYDRO-1,7-NAPHTYRIDIN-8-AMINE SUBSTITUÉS EN POSITION 1
ET LEUR UTILISATION EN TANT QU ANTAGONISTES DU RÉCEPTEUR EP4 |
US10533011B2 (en) | 2015-10-09 | 2020-01-14 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
GB201700814D0 (en) * | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
BR112019020840A2 (pt) | 2017-04-07 | 2020-04-28 | Acea Therapeutics Inc | sais farmacêuticos, formas físicas e composições de inibidores da pirrolopirimidina quinase e métodos de produção dos mesmos |
US11919833B2 (en) * | 2021-04-26 | 2024-03-05 | Mitsubishi Gas Chemical Company, Inc. | Compound and method for producing same |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1582407A (en) * | 1977-06-07 | 1981-01-07 | Worcester Controls Uk Ltd | Annular seals |
US5034393A (en) * | 1989-07-27 | 1991-07-23 | Dowelanco | Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives |
PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
GB9613021D0 (en) * | 1996-06-21 | 1996-08-28 | Pharmacia Spa | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
GB9823845D0 (en) * | 1998-11-02 | 1998-12-23 | Lilly Co Eli | Pharmaceutical compounds |
DE19904710A1 (de) * | 1999-02-05 | 2000-08-10 | Aventis Pharma Gmbh | Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
SE9903290D0 (sv) * | 1999-09-15 | 1999-09-15 | Astra Pharma Prod | Novel compounds |
-
2000
- 2000-10-19 EP EP00971987A patent/EP1230225A2/fr not_active Withdrawn
- 2000-10-19 AU AU10713/01A patent/AU1071301A/en not_active Abandoned
- 2000-10-19 WO PCT/US2000/026261 patent/WO2001032632A2/fr not_active Application Discontinuation
- 2000-10-19 SV SV2000000205A patent/SV2002000205A/es unknown
- 2000-10-20 PE PE2000001131A patent/PE20010854A1/es not_active Application Discontinuation
- 2000-10-27 AR ARP000105680A patent/AR026275A1/es unknown
- 2000-10-27 CO CO00082018A patent/CO5261605A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU1071301A (en) | 2001-05-14 |
WO2001032632A2 (fr) | 2001-05-10 |
WO2001032632A3 (fr) | 2001-11-08 |
AR026275A1 (es) | 2003-02-05 |
EP1230225A2 (fr) | 2002-08-14 |
SV2002000205A (es) | 2002-06-07 |
PE20010854A1 (es) | 2001-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5261605A1 (es) | Compustos farmaceuticos | |
AR016817A1 (es) | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento | |
CO5031253A1 (es) | Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen | |
CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
UY24206A1 (es) | Feniliminoimidazolinas agonistas de alfa 1l útiles en el tratamiento de la incontinencia urinaria. | |
NO914528D0 (no) | N-substituerte heterocykliske derivater, deres fremstilling og farmasoeytiske preparater som inneholder dem | |
CO5070570A1 (es) | DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE | |
CO5450245A1 (es) | Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas | |
CO5261539A1 (es) | Compuestos farmaceuticamente activos | |
AR005706A1 (es) | Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico | |
BR0208678A (pt) | Composto, composição farmacêutica, uso de um composto | |
CO5180622A1 (es) | Compuesto 2-{2-metil-4-[({4-metill-2[4-(trifluorometil)fenil]-1,3-tiazol-5-il]metil) sulfonil]fenoxi]acetico y composicion farmaceutica que lo comprende | |
AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
CO5251467A1 (es) | Derivados de piperazina | |
HUP0302969A2 (hu) | NPY Y5 antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AR033735A1 (es) | Compuestos de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
CO5180629A1 (es) | Pirimidina-2,4,6-ttrionas inhibidores de metaloproteinasas | |
CO5590915A2 (es) | Derivados de piperidina como antagonistas nk1 ( receptor del neuropeptido neuroquinina-1) con actividad antagonista superior en tratamientos de trastornos fisiologicos y disminucion de efectos colaterales | |
PE20050420A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
CO5261565A1 (es) | Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2-tiazolil)-carboxamida de cinasas dependientes de ciclina | |
CO4950553A1 (es) | Compuestos de 7-tetrahidroisoquinolinas y procedimiento para su preparacion | |
AR037928A1 (es) | Compuesto de 2-oxopirrolidin 3- sulfonamida, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento | |
NI200600270A (es) | Una composición farmacéutica antimicobacteriana que comprende un farmaco antituberculosis | |
KR890014502A (ko) | 대뇌-활성 약물 및 중추근이완제로서 사용하기 위한 신규 이소옥사졸 유도체류 | |
KR880011112A (ko) | 벤즈아제핀 설폰아미드 화합물 |